MediXall Group, Inc.

As of September 30, 2024, MediXall Group, Inc. carries a market capitalization of 83,340.40, placing it among publicly traded companies globally. Its enterprise value stands at 659,437.40, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2024, MediXall Group, Inc. has 138.90M shares outstanding.

These figures are as of September 30, 2024. The price-to-sales ratio is 0.28, and the price-to-book ratio stands at -0.02.

These figures are as of September 30, 2024. The EV/Sales ratio of 2.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 659,437.40 versus a market cap of 83,340.40, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2024, MediXall Group, Inc. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -16.80, indicating conservative leverage, while an interest coverage ratio of -1.68 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -640.47, reflecting losses generated across the asset base. The company generates approximately 43,476.57 in revenue per employee across its workforce of 7.00, a quick read on workforce productivity versus industry peers.

As of the close on September 15, 2026, MediXall Group, Inc.'s stock has declined approximately 15.38% over the past 52 weeks. The 50-day moving average sits at 0.25, while the 200-day moving average is 1.06.

Over the twelve months ended September 30, 2024, MediXall Group, Inc. generated 304,336.00 in revenue and converted that into -2.16M in net income, yielding earnings per share of -0.02. EBITDA reached -1.36M, while operating income came in at -1.97M.

As of September 30, 2024, MediXall Group, Inc. holds 31,916.00 in cash and equivalents against 607,925.00 in total debt, resulting in a net debt position of 558,307.00. Total book value stands at -3.62M, with working capital of -3.75M providing operational flexibility.

MediXall Group, Inc. produced -1.20M in operating cash flow over the twelve months ended September 30, 2024.

Over the twelve months ended September 30, 2024, MediXall Group, Inc. posted a gross margin of 57.29, reflecting its pricing power and cost economics. The operating margin of -645.91 and net profit margin of -710.77 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2024. The dividend payout ratio of 11.02 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1,417.02: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1,469.30, meaning MediXall Group, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MediXall Group, Inc.'s most recent stock split took place on December 6, 2016 with a 15:1 split ratio.

As of September 30, 2024, MediXall Group, Inc. has an Altman Z-Score of -865.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.